Amgen is cutting 500 jobs, and its U.S. sales teams are bearing the brunt of it. The California-based drugmaker confirmed Wednesday that it is shrinking its workforce, "primarily in the U.S. sales force," as it pivots to upcoming drug launches and adopts pandemic-time digital marketing tools for the long run. A spokesperson confirmed the total number of jobs is approximately 500.
"We made these changes to better enable Amgen to
make additional investments we believe are needed to take advantage of
patient-focused opportunities, including launching new products, and investing
in R&D," the company said in an emailed statement. "These
decisions are never easy, and we are committed to helping those impacted with
transitional support."